Heymsfield S B, Allison D B, Vasselli J R, Pietrobelli A, Greenfield D, Nunez C
Department of Medicine, Obesity Research Center, St Luke's-Roosevelt Hospital, Columbia University College of Physicians and Surgeons, New York, NY 10025, USA.
JAMA. 1998 Nov 11;280(18):1596-600. doi: 10.1001/jama.280.18.1596.
Hydroxycitric acid, the active ingredient in the herbal compound Garcinia cambogia, competitively inhibits the extramitochondrial enzyme adenosine triphosphate-citrate (pro-3S)-lyase. As a citrate cleavage enzyme that may play an essential role in de novo lipogenesis inhibition, G cambogia is claimed to lower body weight and reduce fat mass in humans.
To evaluate the efficacy of G cambogia for body weight and fat mass loss in overweight human subjects.
Twelve-week randomized, double-blind, placebo-controlled trial.
Outpatient weight control research unit.
Overweight men and women subjects (mean body mass index [weight in kilograms divided by the square of height in meters], approximately 32 kg/m2).
Subjects were randomized to receive either active herbal compound (1500 mg of hydroxycitric acid per day) or placebo, and both groups were prescribed a high-fiber, low-energy diet. The treatment period was 12 weeks. Body weight was evaluated every other week and fat mass was measured at weeks 0 and 12.
Body weight change and fat mass change.
A total of 135 subjects were randomized to either active hydroxycitric acid (n = 66) or placebo (n = 69); 42 (64%) in the active hydroxycitric acid group and 42 (61%) in the placebo group completed 12 weeks of treatment (P = .74). Patients in both groups lost a significant amount of weight during the 12-week treatment period (P<.001); however, between-group weight loss differences were not statistically significant (mean [SD], 3.2 [3.3] kg vs 4.1 [3.9] kg; P = .14). There were no significant differences in estimated percentage of body fat mass loss between treatment groups, and the fraction of subject weight loss as fat was not influenced by treatment group.
Garcinia cambogia failed to produce significant weight loss and fat mass loss beyond that observed with placebo.
藤黄果草本化合物中的活性成分羟基柠檬酸可竞争性抑制线粒体外的三磷酸腺苷 - 柠檬酸（前 - 3S）裂解酶。作为一种可能在抑制从头脂肪生成中起关键作用的柠檬酸裂解酶，藤黄果被宣称可减轻人体体重并减少脂肪量。
评估藤黄果对超重人群体重和脂肪量减轻的疗效。
为期12周的随机、双盲、安慰剂对照试验。
门诊体重控制研究单位。
超重男性和女性受试者（平均体重指数[体重（千克）除以身高（米）的平方]，约为32 kg/m²）。
受试者被随机分配接受活性草本化合物（每日1500毫克羟基柠檬酸）或安慰剂，两组均采用高纤维、低能量饮食。治疗期为12周。每隔一周评估体重，在第0周和第12周测量脂肪量。
体重变化和脂肪量变化。
共有135名受试者被随机分配至活性羟基柠檬酸组（n = 66）或安慰剂组（n = 69）；活性羟基柠檬酸组42名（64%）和安慰剂组42名（61%）完成了12周治疗（P = 0.74）。两组患者在12周治疗期内均显著减重（P<0.001）；然而，组间体重减轻差异无统计学意义（均值[标准差]，3.2 [3.3]千克对4.1 [3.9]千克；P = 0.14）。治疗组间估计的体脂肪量减少百分比无显著差异，且受试者体重减轻中脂肪所占比例不受治疗组影响。
藤黄果未能产生超出安慰剂组的显著体重减轻和脂肪量减少。
